NUVL News and Press, Nuvalent Inc. From 12/22/25

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted thera...

Nuvalent Appoints Ron Squarer to Board of Directors PR Newswire CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically proven...

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted ther...

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders PR Newswire CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage bioph...

2025-11-20 10:48:21 ET Topline Summary And Update Read the full article on Seeking Alpha For further details see: Nuvation Bio: Taking Care With Rapid Rises In Valuation (Rating Downgrade)

2025-11-19 17:42:08 ET More on Nuvalent Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript Nuvalent: Interesting Product, But Aggressive Valuation Nuvalent, Inc. (NUVL) Presents...

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC PR Newswire NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of Septe...

Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass. , Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

A look at the top 10 most actives in the United States UTime Limited (WTO) rose 25.5% to $0.03 on volume of 886,027,496 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.4% to $4.07 on volume of 331,096,152 shares Applied Therapeutics Inc. (APLT) rose 30.2% to $0.2842 on volu...

2025-11-17 16:14:38 ET More on Nuvalent Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript Nuvalent: Interesting Product, But Aggressive Valuation Nuvalent, Inc. (NUVL) Presents...